UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The company’s shares opened today at $121.40. According to ...
mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...
If this EUA application is authorised, children 6 months to under 5 years of age would receive a primary series consisting of two 3-µg doses of the original Pfizer/BioNTech COVID-19 Vaccine ...
After hours: 16 September at 19:44 GMT-4 ...
Tarna Devi temple is best known for its beautiful garbhagriha or sanctum sanctorum, which was significantly renovated by Raja Balbir Singh in the 19 th century. The temple was built by Raja Shyam Sen ...
BARCELONA — Last week, Summit and Akeso set the industry abuzz after their bispecific antibody beat Merck’s Keytruda in a Phase 3 lung cancer trial … ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback